Raloxo 60 mg
Raloxo 60 mg contains Raloxifene, a relatively new anti-estrogen licensed to treat estrogen-related medical problems, osteoporosis and estrogen-responsive breast cancer being the most common. Similar to Nolvadex, Raloxo 60 mg is a supplement taken by anabolic steroid-using bodybuilders to combat and/or avoid Estrogen-related adverse effects and problems (Tamoxifen). Although Raloxo 60 mg / Raloxifene is not as commonly used as Nolvadex for this purpose, accumulating research indicates that it is nearly as effective. Raloxifene is rapidly gaining popularity and interest in the bodybuilding and anabolic steroid-using communities, despite the lack of research and clinical data that more established SERMs like Nolvadex possess. Many within these communities have regarded Raloxifene as a slightly safer alternative, although these claims are currently unfounded.
Raloxifene doses for the treatment and prevention of estrogen-related adverse effects associated with anabolic steroid use are frequently higher than those for more well-known SERMs such as Nolvadex, necessitating bigger Raloxifene doses to combat and control estrogenic side effects. In the field of anabolic steroids, raloxifene is mostly used to treat gynecomastia, with minimal assistance for other estrogenic side effects. As indicated in the beginning of this profile, Raloxifene reduces Estrogen activity in particular tissues rather than lowering overall Estrogen levels in the body. This is a characteristic shared by all SERMs, and it defines how they function. This is essential for anabolic steroid users to remember, since any attempt to prevent extra estrogenic adverse effects such as bloating and water retention with Raloxifene doses will fail. Aromatase inhibitors, on the other hand, accomplish these objectives more effectively.
In addition to its anti-Estrogen effects, Raloxifene has been demonstrated to be an efficient endogenous Testosterone booster, with studies revealing a 20% increase in blood Testosterone levels with 120mg per day. Although not as efficient as Nolvadex, the quantity and intensity of endogenous Testosterone stimulation are sufficient for its use as a post-cycle therapy adjunct (PCT).
Doses of Raloxifene for Medical Use
Raloxo 60 mg (Raloxifene) is a medication licensed by the FDA for the treatment and prevention of osteoporosis by decreasing bone resorption and improving bone ossification (bone formation). Osteoporosis is typically treated with raloxifene in postmenopausal women. Raloxifene is also used to treat postmenopausal women with Estrogen-sensitive breast cancer, as its Estrogen-antagonistic effect stops Estrogen from causing breast cancer.
The recommended daily dose of Raloxo for the treatment of osteoporosis and female breast cancer is one 60 mg tablet. Raloxifene is administered in a single, 60mg dosage with or without food.
Raloxifene Doses When Using Anabolic Steroids
Raloxo, for instance, does not fit into any of the three user groups (beginner, intermediate, or advanced) that are normally defined and included in conventional chemical and pharmacological profiles. Raloxifene is a supplementary medication meant to prevent or reduce Estrogen-related side effects associated with the usage of aromatizable anabolic steroids; it is not used to enhance performance.
Raloxo dosages can also be used to boost endogenous Testosterone secretion in males, allowing this chemical to be utilized as an adjuvant during the PCT (Post Cycle Therapy) stages after an anabolic steroid cycle, however this is unusual and unlikely to result in substantial performance increases.
Raloxo doses are commonly used to prevent the development of gynecomastia during an anabolic steroid cycle that contains aromatizable anabolic steroids or to function as an interceptive medication after gynecomastia has begun. In all instances, raloxifene dosages range from 30 to 60 mg per day throughout an anabolic steroid cycle, with 30 mg being the most common.
It is essential to underline to the reader that the use of Raloxo during an anabolic steroid cycle might negatively impact performance, muscular gain, and strength. Raloxifene, like Nolvadex, has been proven to lower blood IGF-1 levels, a vital muscle development mediator responsible for enhanced nitrogen retention, protein synthesis, and new muscle cell growth5. Comparing IGF-1 levels before and after therapy with Raloxifene, other studies revealed a statistically significant decrease in IGF-1 levels in patients receiving this medication.
SERMs that reduce blood plasma levels of key growth hormones, such as Raloxo and Nolvadex, have a negative effect on muscle growth (namely, IGF-1).
Therefore, it is advised that the period of Raloxifene administration, regardless of the reason (PCT or gynecomastia control/reduction), be maintained as brief as possible to avoid any Estrogen-related side effects associated with the use of aromatizable anabolic steroids. Although short-term Raloxo doses are unlikely to have a substantial effect, long-term medication would have a negative impact on muscle growth and function. In one study of long-term Raloxifene use, researchers discovered that after 24 months of treatment with Raloxifene, test subjects’ IGF-1 levels were much lower than those of the controls. Comparing the effects of Raloxo / Raloxifene and Tamoxifen (Nolvadex) on men, another study indicated that Raloxifene had no significant effect on IGF-1 compared to Nolvadex[8]. In one trial of acromegaly, 120mg of Raloxifene provided twice daily (in split doses of 60mg twice day) decreased IGF-1 levels by 16% [9]. Given the small number of studies that demonstrated no statistically significant reductions in IGF-1 levels, any potential anabolic steroid user should examine the effects of Raloxifene dosages.
SERMs that reduce blood plasma levels of key growth hormones, such as Raloxo and Nolvadex, have a negative effect on muscle growth (namely, IGF-1). Therefore, it is advised that the period of Raloxifene administration, regardless of the reason (PCT or gynecomastia control/reduction), be maintained as brief as possible to avoid any Estrogen-related side effects associated with the use of aromatizable anabolic steroids. Although short-term Raloxifene doses are unlikely to have a substantial effect, long-term usage would have a negative impact on muscle growth and function. In one study of long-term Raloxifene usage, researchers discovered that after 24 months of treatment, test subjects’ IGF-1 levels were much lower than those of controls[7]. Comparing the effects of Raloxifene and Tamoxifen (Nolvadex) on males, another study indicated that Raloxifene had no significant effect on IGF-1 compared to Nolvadex. In one trial of acromegaly, 120mg of Raloxifene provided twice daily (in divided doses of 60mg twice day) decreased IGF-1 levels by 16%. Given the small number of studies that demonstrated no statistically significant reductions in IGF-1 levels, any potential anabolic steroid user should examine the effects of Raloxifene dosages.
Leave feedback about this